Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 1/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | ACHE | P22303 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | BTN3A1 | O00481 | 4/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10615801 | 0.94 | FDPS (0.47) | FDPSBLMTDP1ACHEALDH1A1 | |
| SCHEMBL1758661 | 0.94 | FDPS (0.53) | FDPSBLMTDP1ACHEALDH1A1 | |
| SCHEMBL7737476 | 0.91 | FDPS (0.50) | FDPSBLMTDP1ACHEALDH1A1 | |
| SCHEMBL10601758 | 0.91 | FDPS (0.50) | FDPSBLMTDP1ACHEALDH1A1 | |
| SCHEMBL11407406 | 0.91 | FDPS (0.50) | FDPSBLMTDP1ACHEALDH1A1 | |
| SCHEMBL16855771 | 0.89 | FDPS (0.43) | FDPSBLMTDP1ACHEALDH1A1 | |
| SCHEMBL15760477 | 0.84 | FDPS (0.43) | FDPSBLMTDP1ACHEALDH1A1 | |
| Ethylene Glycol SCHEMBL29066335 | 0.84 | FDPS (0.43) | FDPSBLMTDP1ACHEALDH1A1 | |
| SCHEMBL9767572 | 0.80 | FDPS (0.45) | FDPSBLMTDP1ACHEALDH1A1 | |
| SCHEMBL28938232 | 0.80 | FDPS (0.39) | FDPSBLMTDP1ACHEALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112004942-A | Analysis and diagnosis method using RNA modification | 国立大学法人大阪大学 | 2020-11-27 | — | — | CN | disclosed |
| CN-105102534-A | Resin composition and film thereof | KANEKA CORP | 2015-11-25 | — | — | CN | disclosed |
| CN-101675110-B | Polycarbonate resin composition | TEIJIN LTD | 2013-04-10 | — | — | CN | disclosed |
| US-7807653-B2 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2010-10-05 | — | — | US | disclosed |
| CN-101675110-A | Polycarbonate resin composition | TEIJIN LTD | 2010-03-17 | — | — | CN | disclosed |
| US-7598230-B2 | For the treatment of viral infections, microbial infections, and proliferative disorders; contain di- or triphosphate moeity mimetics, such as those containing boron anions | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2009-10-06 | — | — | US | disclosed |
| CN-101300031-A | Use of SDF-1 for the treatment and/or prevention of neurological diseases | SERONO LAB (CH) | 2008-11-05 | — | — | CN | disclosed |
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-15 | — | — | US | disclosed |
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2007-11-08 | — | — | US | disclosed |
| US-7285658-B2 | Nucleotide mimics and their prodrugs | BIOTA, INC. (US) | 2007-10-23 | — | — | US | disclosed |
| EP-1485395-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | Biota, Inc. (US) | 2004-12-15 | — | — | EP | disclosed |
| WO-2003072757-A9 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA INC (US) | 2004-10-21 | — | — | WO | disclosed |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | BIOTA SCIENTIFIC MANAGEMENT PTY LTD (AU) | 2004-03-25 | — | — | US | disclosed |
| WO-2003072757-A2 | NUCLEOTIDE MIMICS AND THEIR PRODRUGS | BIOTA, INC. (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070259832-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | FDPS 145/4885BLM 1763/4885TDP1 961/4885 |
| US-20070265224-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | FDPS 145/4885BLM 1763/4885TDP1 961/4885 |
| US-20040059104-A1 | Nucleotide mimics and their prodrugs | NUDT14, ENTPD5, MTAP | FDPS 145/4885BLM 1763/4885TDP1 961/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.